A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs GBR 1342 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 12 Oct 2017 Status changed from planning to not yet recruiting.
- 23 May 2017 New trial record
- 15 May 2017 According to a Glenmark Pharmaceuticals media release, the US FDA has cleared the company's IND application to initiate a phase I study of GBR 1342.